Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
22 October 2021Website:
http://www.xiliotx.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 22:43:08 GMTDividend
Analysts recommendations
Institutional Ownership
XLO Latest News
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company's board of directors.
Xilio (XLO) surges by 79.8% in just one month following the announcement of an exclusive worldwide licensing agreement with Gilead Sciences for the development of XTX301 for advanced solid tumors.
Xilio Therapeutics (NASDAQ: XLO ) stock is rocketing higher on Thursday after the clinical-stage biotechnology company signed an exclusive license agreement with Gilead Sciences (NASDAQ: GILD ). This agreement has Gilead taking over the development and commercialization responsibilities of Xilio Therapeutics' XTX301.
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, which will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023.
What type of business is Xilio Therapeutics?
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
What sector is Xilio Therapeutics in?
Xilio Therapeutics is in the Healthcare sector
What industry is Xilio Therapeutics in?
Xilio Therapeutics is in the Biotechnology industry
What country is Xilio Therapeutics from?
Xilio Therapeutics is headquartered in United States
When did Xilio Therapeutics go public?
Xilio Therapeutics initial public offering (IPO) was on 22 October 2021
What is Xilio Therapeutics website?
https://www.xiliotx.com
Is Xilio Therapeutics in the S&P 500?
No, Xilio Therapeutics is not included in the S&P 500 index
Is Xilio Therapeutics in the NASDAQ 100?
No, Xilio Therapeutics is not included in the NASDAQ 100 index
Is Xilio Therapeutics in the Dow Jones?
No, Xilio Therapeutics is not included in the Dow Jones index
When does Xilio Therapeutics report earnings?
The next expected earnings date for Xilio Therapeutics is 14 August 2024